PREScribing INFORMATION

K-10®
(Potassium Chloride Oral Solution, 10% USP)

POTASSIUM REPLACEMENT THERAPY

GlaxoSmithKline Inc
7333 Mississauga Road North
Mississauga, Ontario L5N 6L4

Date of Revision: April 14, 2015
Submission Control No: 210909

©2015 GlaxoSmithKline Inc. All Rights Reserved
K-10 is a registered trademark of SmithKline Beecham Pharma Inc., used under license by GlaxoSmithKline Inc.
PRESCRIBING INFORMATION

NAME OF DRUG
K-10®
(Potassium Chloride Oral Solution, 10% USP)

THERAPEUTIC CLASSIFICATION
Potassium Replacement Therapy

INDICATIONS
The prevention and treatment of hypokalemic states which may occur in conjunction with diuretic therapy, digitalis intoxication, corticosteroid therapy, inadequate dietary intake, loss of potassium due to vomiting and diarrhea, hypochloremic alkalosis, diabetic acidosis, and familial periodic paralysis as well as other causes.

CONTRAINDICATIONS
Potassium chloride is contraindicated in patients with: Adrenal insufficiency (Addison’s disease), conditions involving extensive cell destruction (e.g. severe burns), congenital paramyotonia, acute dehydration, exacerbations of peptic ulcer disease, gastrointestinal bleeding (see WARNINGS AND PRECAUTIONS), hyperkalemia, hyperkalaemic periodic paralysis, hypersensitivity to any of the preparation’s ingredient, hyporeninaemic hypoaldosteronism, metabolic acidosis (due to uncontrolled diabetes), renal failure, concomitant treatment with a potassium-sparing diuretic alone or in combination with a saluretic-diuretic agent (see INTERACTIONS).

INTERACTIONS
Potassium serum concentration should be periodically measured during concomitant administration of drugs which interact with this product. Increase of potassium serum concentration may occur when potassium chloride is used simultaneously with: potassium sparing diuretics, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-II receptor blockers, cyclosporin, nonsteroidal anti inflammatory drugs - NSAIDS (e.g. indomethacin, heparin, cardiac glycosides, β-adrenolytics and other potassium-containing products (see CONTRAINDICATIONS).

Potassium-sparing diuretics
Concomitant use of potassium chloride and potassium-sparing diuretics such as amiloride, canrenone, spironolactone, triamterene (alone or in combination) is contraindicated (see CONTRAINDICATIONS). Risk of potentially lethal hyperkalemia is particularly high in patients with kidney failure (added effects of potassium-sparing
ACE inhibitors
Concomitant use of potassium chloride with angiotensin-converting-enzyme (ACE) inhibitors is not recommended except in the case of hypokalemia. Concomitant use of these medicinal products induces a risk of potentially lethal hyperkalemia particularly in patients with kidney failure.

Cardiac glycosides
Special caution should be used in concomitant use of the potassium chloride and cardiac glycosides. Hyperkalemia may cause atrioventricular conductivity disorders.

Non-steroid anti-inflammatory drugs
Special caution should be used in concomitant use of the potassium chloride and non-steroid anti-inflammatory drugs. Non-steroid anti-inflammatory drugs may cause hyperkalemia. During concomitant treatment with these drugs control of serum potassium concentration is necessary.

WARNINGS AND PRECAUTIONS

Treatment Monitoring
Potassium chloride must be administered cautiously, since the degree of deficiency or the ideal daily dosage often is not accurately known. Excessive dosage may give rise to potassium intoxication. Frequent checks of the clinical status of the patient, and the periodic ECG and/or serum potassium levels should be made before and during treatment.

Potassium intoxication may result from overdosage of potassium or from therapeutic dosage in conditions stated under CONTRAINDICATIONS.

Ability to perform tasks that require judgement, motor or cognitive skills
The drug has no effect on the ability to drive vehicles and operate machinery.

Cardiac
This drug should be used with caution in the presence of cardiac disease.

Elderly
Potassium chloride should be used with special caution in elderly patients.

Fertility
There are no relevant data available.

Gastrointestinal
Potassium chloride should be withdrawn in the presence of severe abdominal pain,
hematemesis and black feces (see CONTRAINDICATIONS). Potassium chloride, alone or in combination with other medications may induce ulceration in the gastrointestinal tract, in particular the lower esophagus and small bowel. This possibility is increased in patients with local, functional or mechanical disorders of the gastrointestinal tract, with cardiovascular disease, or in those on prolonged therapy or receiving anticholinergics. Symptoms or signs suggesting ulceration or obstruction of the tract should be regarded as reasons to discontinue medication immediately. Patients with ostomies may have altered intestinal transit times and are better treated with other forms of potassium salts.

**Hepatic**
Potassium salts should only be administered with extreme caution to patients with hepatic disease (because of the risk of hyperkalaemia).

**Lactation**
The drug may be given to breast-feeding women only if in the physician's judgement the benefit for the mother outweighs the potential risk to the fetus.

**Pregnancy**
The drug may be given to pregnant women only if in the physician's judgement the benefit for the mother outweighs the potential risk to the fetus. There is no data on the risk for the fetus in humans and animals, as no properly controlled clinical trials have been conducted.

**Renal**
The administration of lower potassium doses should be considered in patients with renal disorders. Kalemia, ECG and renal function should periodically be monitored during therapy with potassium preparation (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).

**Other**
In some patients, diuretic induced magnesium deficiency will prevent restoration of intracellular deficits of potassium so that hypomagnesaemia should be corrected at the same time as hypokalaemia.

**ADVERSE REACTIONS**

**Cardiac disorders**
Arrhythmia, atrioventricular conduction disorders.

**Gastrointestinal disorders**
Nausea, vomiting, flatulence, abdominal pain, abdominal discomfort, diarrhea, burning sensation in the stomach and esophagus, constipation, small intestine erosions, obstruction, hemorrhage and gastroduodenal ulceration.
The risk of gastroduodenal ulceration increases at high doses of potassium chloride. Cases of small intestine ulceration have been reported.

Metabolism and nutrition disorders
Hyperkalemia (with risk of sudden death). Hyperkalemia should be prevented by monitoring potassium levels (see WARNINGS AND PRECAUTIONS).

Skin and subcutaneous tissue disorders
Skin rash, pruritus, urticaria

OVERDOSAGE

Symptoms
The severity of symptoms depends on the severity of hyperkalemia. The symptoms of potassium chloride overdose may include cardiovascular events (hypotension, shock, ventricular arrhythmias, bundle-branch block, and ventricular fibrillation leading possibly to cardiac arrest) and neuromuscular events (paraesthesiae, convulsions, areflexia, flaccid paralysis of striated muscle leading possibly to respiratory paralysis). Beside elevation of serum potassium concentration, typical ECG changes are also encountered (increasing amplitude and peaking of T waves, disappearance of P wave, widening of QRS complex and S-T segment depression).

Treatment
The drug should be withdrawn if overdose symptoms occur. Considerable overdose requires hospitalization.

DOSAGE AND ADMINISTRATION

Adults: Take as directed by a physician. One tablespoonful (15 mL) twice daily, dissolved completely in 100-250 mL of cold water, juice or other liquid. Take with food or immediately after meals and drink slowly (to minimize gastrointestinal irritation and prevent too rapid absorption). Deviation from this recommendation may be indicated since no average total daily dose can be defined but must be governed by close observation for clinical effects. In determining dosage, it has to be remembered that fruits, vegetables and their juices contain potassium. Patients should be cautioned to follow directions explicitly in regard to dilution of K-10® to prevent gastrointestinal injury.

Children: There are no relevant data available.

Elderly: Potassium chloride should be used with special caution in elderly patients.

For management of a suspected drug overdose, contact your regional Poison Control Centre.
**Renal impairment:** Potassium chloride is contraindicated in patients with renal failure (see CONTRAINDICATIONS and INTERACTIONS).

**Hepatic impairment:** There are no relevant data available.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

K-10® (potassium chloride oral solution, 10% USP) is a clear, colourless liquid with a characteristic lemon taste.

Each tablespoon (15 mL) contains potassium chloride 1.5 g (supplying 20 mEq of elemental potassium) and the following non-medicinal ingredients: calcium cyclamate, citric acid, glycerin, lemon flavour, orange flavour, purified water and sodium benzoate. Available in bottles of 500 mL.
CONSUMER INFORMATION

K-10®
(Potassium Chloride Oral Solution, 10% USP)

This leaflet is a part of "Prescribing Information" for K-10® and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about K-10®. Contact your doctor or pharmacist if you have any questions about this product.

ABOUT THIS MEDICATION

What the medication is used for:

K-10® is a mineral supplement used to treat or prevent low amounts of potassium in the blood. Potassium is found naturally inside your body and in different foods and is necessary for many normal functions of the body.

What it does:

K-10® helps restore or keep the proper amount of potassium in your body. Levels of potassium can be low as a result of a disease or from taking some medicines, the type of food you’re eating, or after a prolonged illness with diarrhea or vomiting.

When it should not be used:

You should not use K-10® if you:

- have a condition in which your adrenal glands do not make enough of some hormones (Addison’s disease)
- have severe burns or other tissue damage
- have genetic muscular conditions (congenital paramyotonia)
- are dehydrated
- have peptic ulcer disease
- have blood in stool
- have high levels of potassium in your blood (hyperkalemia)
- suffer from muscle weakness or muscle spasms (hyperkalaemic periodic paralysis)
- have had allergic reactions to K-10® or potassium chloride or any of the ingredients in K-10®
- have low levels of an enzyme called renin and a hormone called aldosterone which normally help to control your blood pressure (hyporeninaemic hypoaldosteronism)
- have metabolic acidosis (due to uncontrolled diabetes)
- have kidney failure
- are taking potassium sparing diuretics (“water pills”) such as canrenone, spironolactone or triamterene,

What the medicinal ingredient is:

Each tablespoon (15 mL) contains 1.5 g potassium chloride.

What the nonmedicinal ingredients are: Calcium cyclamate, citric acid, glycerin, lemon flavour, orange flavour, purified water and sodium benzoate.

What dosage forms it comes in:

K-10® is a clear, colourless liquid with a lemon taste. It comes in 500 mL bottles.

WARNINGS AND PRECAUTIONS

BEFORE you use K-10® talk to your doctor or pharmacist if you:

- have heart disease
- are over 65 years old
- have severe abdominal pain, are vomiting blood or pass black stool
- are pregnant or breastfeeding
- have kidney or liver disease

INTERACTIONS WITH THIS MEDICATION

Talk to your doctor if you are taking any of these medications:

- angiotensin-converting-enzyme (ACE) inhibitors such as enalapril or lisinopril (used to treat high blood pressure and some heart conditions)
- angiotensin-II receptor blockers such as losartan (used to treat high blood pressure)
- cyclosporin (used to prevent rejection after organ transplantation)
- nonsteroidal anti inflammatory drugs (NSAIDS) such as indomethacin (used to treat pain and inflammation)
- heparin (used to prevent blood clots),
- cardiac glycosides (used to treat heart failure)
- β-blockers or other heart medication
- other potassium-containing products

PROPER USE OF THIS MEDICATION

Usual adult dose:

One tablespoonful (15 mL) twice daily, dissolved completely in 100-250 mL of cold water, juice or other liquid as directed by your doctor. Take with food or immediately after meals and drink slowly.
**Overdose:**

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

If you accidentally take a larger dose of K-10® (i.e. more drug than recommended by your doctor), you may feel shortness of breath, feel like your heart is beating faster than normal or beating unevenly, feel dizzy or lightheaded, or experience muscle weakness or tingling sensation on your skin.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

- Fast or irregular heartbeat
- Dizziness, shortness of breath
- Gas, nausea or vomiting, burning sensation in the throat, chest and stomach
- Diarrhea, stomach pain, constipation
- Muscle weakness and tingling sensation
- Skin rash, itching

Talk with your doctor or pharmacist in all cases

This is not a complete list of side effects. For any unexpected effects while taking K-10®, contact your doctor or pharmacist.

**REPORTING SUSPECTED SIDE EFFECTS**

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
    Health Canada
    Postal Locator 0701E
    Ottawa, Ontario
    K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

**NOTE:** Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

**MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals can be found at:

http://www.gsk.ca or by contacting the sponsor,

GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
1-800-387-7374

This leaflet was prepared by GlaxoSmithKline Inc.

Last revised: April 14, 2015

©2015 GlaxoSmithKline Inc. All Rights Reserved
K-10 is a registered trademark of SmithKline Beecham Pharma Inc., used under license by GlaxoSmithKline Inc.